Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2014

Open Access 01-12-2014 | Research

Multivariate epidemiologic analysis of type 2 diabetes mellitus risks in the Lebanese population

Authors: Michella Ghassibe-Sabbagh, Mary Deeb, Angelique K Salloum, Francis Mouzaya, Marc Haber, Yasser Al-Sarraj, Youssef Chami, Yasmine Akle, Kamal Hirbli, Rita Nemr, Rechdi Ahdab, Daniel E Platt, Antoine B Abchee, Hatem El-Shanti, Pierre A Zalloua

Published in: Diabetology & Metabolic Syndrome | Issue 1/2014

Login to get access

Abstract

Background

The burden of diabetes in Lebanon requires well-targeted interventions for screening type 2 diabetes mellitus (T2DM) and prediabetes and prevention of risk factors. Newly recruited 998 Lebanese individuals, in addition to 7,292 already available, were studied to investigate the prevalence of diabetes, prediabetes and their associated risk factors.

Methods

Participants had fasting blood sugar and glycohemoglobin tests in addition to a lipid profile. Clinical and demographic information were obtained from a detailed questionnaire. The relationship between T2DM, its risk factors, and its complications were tested. Comparisons of these risk factors among diabetics, healthy, and coronary artery disease (CAD) patients were performed.

Results

The prevalence of T2DM significantly increased with increasing BMI (p < 0.0001). Exercise activity level negatively correlated with the disease (p = 0.002), whereas the prevalence of T2DM (p < 0.0001) and CAD family history (p = 0.006) positively correlated with the affection status. The mean levels of triglycerides and LDL-C were significantly higher in diabetics (1.87; 1.35) compared to individuals with prediabetes (1.63; 1.26) and unaffected controls (1.49; 1.19). People with T2DM showed a significant decrease in HDL-C levels. A strong correlation of overall hyperlipidemia with the diabetes affection status was shown (p < 0.0001). Other comorbid factors such as hypertension (p < 0.0001) and self-reported obesity (p < 0.0001) were highly associated with T2DM and prediabetes. Reproductive health of women showed a strong correlation between giving birth to a baby with a high weight and the occurrence of T2DM and prediabetes later in life (p < 0.0001). Retinopathy and peripheral neuropathy were significantly correlated with diabetes and prediabetes (p < 0.0001).

Conclusions

The present study shows an alarming prevalence of diabetes and prediabetes in the studied subgroups representative of the Lebanese population.
Appendix
Available only for authorised users
Literature
1.
2.
Hager J, Kamatani Y, Cazier JB, Youhanna S, Ghassibe-Sabbagh M, Platt DE, Abchee AB, Romanos J, Khazen G, Othman R, Badro DA, Haber M, Salloum AK, Douaihy B, Shasha N, Kabbani S, Sbeite H, Chammas E, el Bayeh H, Rousseau F, Zelenika D, Gut I, Lathrop M, Farrall M, Gauguier D, Zalloua PA: Genome-wide association study in a Lebanese cohort confirms PHACTR1 as a major determinant of coronary artery stenosis. PLoS One. 2012, 7: e38663-10.1371/journal.pone.0038663.PubMedCentralCrossRefPubMed
3.
4.
R Development Core Team: R: a language and environment for statistical computing. 2013, Vienna, Austria: R Foundation for Statistical Computing, ISBN 3-900051-07-0
5.
6.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002, 346: 393-403.CrossRefPubMed
7.
Chiu M, Austin PC, Manuel DG, Shah BR, Tu JV: Deriving ethnic-specific BMI cutoff points for assessing diabetes risk. Diabetes Care. 2011, 34: 1741-1748. 10.2337/dc10-2300.PubMedCentralCrossRefPubMed
8.
Ma RC, Chan JC: Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013, 1281: 64-91. 10.1111/nyas.12098.PubMedCentralCrossRefPubMed
9.
al-Mahroos F, al-Roomi K: Overweight and obesity in the Arabian Peninsula: an overview. J R Soc Promot Health. 1999, 119: 251-253. 10.1177/146642409911900410.CrossRefPubMed
10.
Bellamy L, Casas JP, Hingorani AD, Williams D: Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009, 373: 1773-1779. 10.1016/S0140-6736(09)60731-5.CrossRefPubMed
11.
Catalano PM, Hauguel-De Mouzon S: Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic?. Am J Obstet Gynecol. 2011, 204: 479-487. 10.1016/j.ajog.2010.11.039.PubMedCentralCrossRefPubMed
12.
Leikin EL, Jenkins JH, Pomerantz GA, Klein L: Abnormal glucose screening tests in pregnancy: a risk factor for fetal macrosomia. Obstet Gynecol. 1987, 69: 570-573.PubMed
13.
Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA: Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008, 358: 1991-2002.CrossRefPubMed
14.
Sacks DA: Etiology, detection, and management of fetal macrosomia in pregnancies complicated by diabetes mellitus. Clin Obstet Gynecol. 2007, 50: 980-989. 10.1097/GRF.0b013e31815a6242.CrossRefPubMed
15.
Boney CM, Verma A, Tucker R, Vohr BR: Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005, 115: e290-296. 10.1542/peds.2004-1808.CrossRefPubMed
16.
Group HSCR: Hyperglycemia and adverse pregnancy outcome (HAPO) study: associations with neonatal anthropometrics. Diabetes. 2009, 58: 453-459.CrossRef
17.
Sibai AM, Hwalla N, Adra N, Rahal B: Prevalence and covariates of obesity in Lebanon: findings from the first epidemiological study. Obes Res. 2003, 11: 1353-1361. 10.1038/oby.2003.183.CrossRefPubMed
18.
Valdez R: Detecting undiagnosed type 2 diabetes: family history as a risk factor and screening tool. J Diabetes Sci Technol. 2009, 3: 722-726. 10.1177/193229680900300417.PubMedCentralCrossRefPubMed
19.
Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003, 26 (Suppl 1): S83-86.PubMed
20.
Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000, 101: 975-980. 10.1161/01.CIR.101.9.975.CrossRefPubMed
21.
Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA. 1990, 263: 2893-2898. 10.1001/jama.1990.03440210043030.CrossRefPubMed
22.
Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004, 27: 1496-1504. 10.2337/diacare.27.6.1496.CrossRefPubMed
23.
Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D: Diabetic neuropathies: a statement by the American diabetes association. Diabetes Care. 2005, 28: 956-962. 10.2337/diacare.28.4.956.CrossRefPubMed
24.
Dyck PJ, Davies JL, Wilson DM, Service FJ, Melton LJ, O’Brien PC: Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care. 1999, 22: 1479-1486. 10.2337/diacare.22.9.1479.CrossRefPubMed
25.
Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H: Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001, 44 (Suppl 2): S14-21.CrossRefPubMed
26.
Hirbli KI, Jambeine MA, Slim HB, Barakat WM, Habis RJ, Francis ZM: Prevalence of diabetes in greater Beirut. Diabetes Care. 2005, 28: 1262-CrossRefPubMed
27.
28.
Centers for Disease Control and Prevention (CDC): Increasing prevalence of diagnosed diabetes--United States and Puerto Rico, 1995–2010. MMWR Morb Mortal Wkly Rep. 2012, 61: 918-921.
Metadata
Title
Multivariate epidemiologic analysis of type 2 diabetes mellitus risks in the Lebanese population
Authors
Michella Ghassibe-Sabbagh
Mary Deeb
Angelique K Salloum
Francis Mouzaya
Marc Haber
Yasser Al-Sarraj
Youssef Chami
Yasmine Akle
Kamal Hirbli
Rita Nemr
Rechdi Ahdab
Daniel E Platt
Antoine B Abchee
Hatem El-Shanti
Pierre A Zalloua
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2014
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-6-89

Other articles of this Issue 1/2014

Diabetology & Metabolic Syndrome 1/2014 Go to the issue

Research

The relationship between regional abdominal fat distribution and both insulin resistance and subclinical chronic inflammation in non-diabetic adults

Research

A potential link between endothelial function, cardiovascular risk, and metabolic syndrome in patients with Non-alcoholic fatty liver disease

Research

Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

Research

Fiber intake and inflammation in type 1 diabetes

Research

Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague–Dawley rats

Research

The association of body mass index with the risk of type 2 diabetes: a case–control study nested in an electronic health records system in the United States

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits